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Abstract
Background: Interleukin-6 (IL-6) is a pro-inflammatory cytokine that has been found to be increased in type 2 diabetic
subjects. However, it still remains unclear if these elevated IL-6 levels are co-incidental or if this cytokine is causally related to
the development of insulin resistance and type 2 diabetes in humans. Therefore, in the present study we examined insulin
sensitivity, serum adipokine levels and lipid parameters in human subjects before and after treatment with the IL-6 receptor
antibody Tocilizumab.
Methodology/Principal Findings: 11 non-diabetic patients with rheumatoid disease were included in the study. HOMA-IR
was calculated and serum levels for leptin, adiponectin, triglycerides, LDL-cholesterol, HDL-cholesterol and lipoprotein (a)
(Lp (a)) were measured before as well as one and three months after Tocilizumab treatment. The HOMA index for insulin
resistance decreased significantly. While leptin concentrations were not altered by inhibition of IL-6 signalling, adiponectin
concentrations significantly increased. Thus the leptin to adiponectin ratio, a novel marker for insulin resistance, exhibited a
significant decrease. Serum triglycerides, LDL-cholesterol and HDL-cholesterol tended to be increased whereas Lp (a) levels
significantly decreased.
Conclusions/Significance: Inhibition of IL-6 signalling improves insulin sensitivity in humans with immunological disease
suggesting that elevated IL-6 levels in type 2 diabetic subjects might be causally involved in the pathogenesis of insulin
resistance. Furthermore, our data indicate that inhibition of IL-6 signalling decreases Lp (a) serum levels, which might reduce
the cardiovascular risk of human subjects.
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Introduction
The prevalence of obesity and type 2 diabetes is increasing
rapidly in most industrialised countries throughout the world [1].
These metabolic abnormalities can lead to alterations within the
vascular wall inducing atherosclerosis [2] which may result in
myocardial infarction, stroke and renal dysfunction thereby
reducing life expectancy [3]. An increasing number of clinical
and experimental studies suggest that inflammatory mechanisms
are important in the pathogenesis of type 2 diabetes. For example,
it has been shown that in obese and type 2 diabetic human subjects
adipocytes secrete increasing levels of chemokines compared to
lean controls [4]. Of these, monocyte chemotactic protein (MCP)-1 is
known to attract blood monocytes into adipose tissue where they
transform into macrophages [5]. These cells are able to secret a
huge array of pro-inflammatory cytokines, e. g. tumor necrosis factor
(TNF)-a and interleukins (IL) [5]. Of these, TNF-a has been shown
to alter adipogenesis [6] and to inhibit insulin signalling in mice [7]
suggesting that low-grade inflammation induces insulin resistance.
Within the last decade, monoclonal antibodies against specific pro-
inflammatory cytokines have become increasingly important in the
treatment of severely active immunological diseases. For example, the
anti-TNF-a antibodies infliximab [8], adalimumab [9], golimumab
[10]and certolizumab [11] arecommonlyused inclinicalpracticefor
the treatment of patients with rheumatoid arthritis. Besides these
monoclonal antibodies, other so-called ‘‘biologicals’’ have been
developed, e. g. the soluble TNF-a receptor etanercept [12] as well
as the recombinant IL-1 receptor antagonist anakinra [13], which is
known to be highly effective in cases of Still’s syndrome.
Biologicals are not only very effective drugs for treatment of
immunological diseases but are also very elegant tools for
translational research. Since the cytokines causing classical
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promote low-grade inflammation in the pathogenesis of insulin
resistance and type 2 diabetes, clinical investigation of the effects of
TNF-a and interleukin-1 inhibitors in human subjects on metabolic
parameters has previously been undertaken. For example, Rosen-
vinge A. et al. examined insulin sensitivity by hyperinsulinaemic
euglycaemic clamp studies in patients with rheumatoid arthritis
before and 8 weeks after adalimumab treatment [14]. Interestingly,
they did not observe a significant effect of anti-TNF-a treatment on
insulin sensitivity. This finding has been confirmed by Dominguez
et al. in a cohort of 20 obese patients with type 2 diabetes where
etanercept treatment did not affect insulin sensitivity [15]. These
observations raise the question, whether low-grade inflammation is
important at all in the development of type 2 diabetes in the human
organism or if elevated inflammatory markers are only epiphenom-
ena. However, in a double-blinded, parallel-group trial involving 70
patients with type 2 diabetes anakinra treatment for 13 weeks
lowered glycosylated haemoglobin-A1c levels by 0.46% compared
to placebo [16]. Interestingly, this improvement of glycemic control
was not due to enhanced insulin sensitivity but rather due to
improved b-cell secretory function [16] suggesting that IL-1 is more
involved in maintaining b-cell homeostasis than in adipose tissue
biology in human subjects with type 2 diabetes.
Of the many interleukins identified, IL-6 exhibits a strong
association with insulin resistance in human subjects [17]. In 2009 a
monoclonal antibody against the IL-6 receptor, called Tocilizumab,
was approved for treatment of rheumatoid arthritis in Europe. Since
translational research within the last few years failed to demonstrate
an important role for TNF-ain inducing insulin resistance in humans,
in the present study we aimed to examine if IL-6 might be of clinical
relevance in this context by measuring insulin sensitivity, adipokine
serum levels and lipid parameters in patients with immunological
d i s e a s eb e f o r ea n da t1a n d3m o n ths of Tocilizumab therapy.
Methods
Study cohort
The study was approved by the local ethics committee (Ethik
Kommission, Universita ¨t zu Ko ¨ln). Written informed consent was
obtained from each subject before including into the study. A total
number of n=11 human subjects with rheumatoid disease were
included. 7 were females, 4 were men. Mean age was 50.764.4
years. Inclusion criteria were: age between 20 and 70 years and
caucasian descent. Exclusion criteria were: acute or chronic
infections, cancer, elevations of liver indices more than 3-fold
greater than the top of the normal range, serum-creatinine levels
.1.5 mg/dl, or pregnancy. Mean body mass index (BMI) was
28.061.8 kg/m
2. None of the patients was diagnosed with type 1
or type 2 diabetes. All patients were treated with steroids at doses
of #10 mg/d prednisone equivalent (table 1). Patients were
advised not to change the steroid dosage throughout the 3 month
study period.
Biochemical analysis
Blood samples were taken after a 12 h fasting period,
centrifuged at 1000 rpm and serum samples were stored at
280uC before measurements were performed. Glucose levels were
measured by the oxidase method. Triglycerides were determined
by enzymatic colorimetric assay (Roche Diagnostics). LDL- and
HDL-cholesterol were measured by a homogeneous direct method
(Roche Diagnostics). Lipoprotein (a) (Lp (a)) was determined by
turbidometry (Roche Diagnostics). C-reactive Protein levels were
also measured by turbidometry (CRPL3, Roche Diagnostics) with
an analytical sensitivity of 0.3 mg/l. Insulin and IL-6 levels were
measured by chemiluminescence (Immulite 2000 insulin, Siemens
(Germany), analytical-sensitivity: 2 mIU/ml, Immulite IL-6, Sie-
mens (Germany), analytical-sensitivity: 2 pg/ml). ELISA for
adipokine measurement were purchased from IBL International
as follows: Adiponectin ELISA order number: BV51001 (analyt-
ical-sensitivity: 0,2 mg/ml), Leptin ELISA order number RE53151
(analytical-sensitivity: 1,0 ng/ml). The ELISA were performed
according to the instructions of the manufacturer.
Body composition analysis
Body fat content was analyzed by dual-X-ray-absorptiometry
(Lunar-Prodigy-Advance (GE Healthcare)).
Table 1. Demographic, anthropometric and clinical characteristics of the study population.
patient sex age (a) weight (kg) hight (m) BMI (kg/m2)
body fat
(%) current medication
1 f 67,00 54,00 1,54 22,77 36,60 Prednisone 5 mg/d, Methotrexate 10 mg/week
2 m 38,00 113,00 1,88 31,97 34,90 Prednisone 7,5 mg/d, Colchicin 1,5 mg/d, Allopurinol 300 mg/d,
Pantoprazol 20 mg/d
3 m 64,00 73,00 1,82 22,04 20,50 Prednsione 10 mg/d, Leflunomide 20 mg/d, Omeprozol 20 mg/
d, Simvastatin 40 mg/d
4 m 60,00 119,00 1,75 38,86 41,10 Prednisone 10 mg/d, Simvastatin 40 mg/d, Enalapril 5 mg/d,
Torasemide 10 mg/d
5 f 55,00 92,00 1,68 32,60 50,00 Prednsione 10 mg/d, Leflunomide 20 mg/d
6 f 44,00 61,00 1,73 20,38 34,50 Methyl-Prednisolone 4 mg/d
7 m 41,00 94,00 1,83 28,07 32,90 Prednisone 5 mg/d, Leflunomide 10 mg/d, Esomeprazol 20 mg/d
8 f 69,00 81,00 1,64 30,12 - Prednsione 10 mg/d, Alendronate 70 mg/week
9 f 48,00 64,00 1,69 22,41 39,10 Prednisone 5 mg/d
10 f 21,00 78,00 1,76 25,18 44,40 Prednisone 10 mg/d, Leflunomide 20 mg/d, Omeprazol 20 mg/d,
Phenprocoumone 1,5 mg/d
11 f 44,00 90,00 1,68 31,89 48,50 Prednsione 5 mg/d
BMI = body mass index, f= female, m= male. Means 6 SEM.
doi:10.1371/journal.pone.0014328.t001
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The groups were compared using Wilxocon-Tests. Correlation
was examined using Spearman’s rank correlation coefficient.
p,0.05 was considered to be significant. Data are given as mean
6 SEM. The HOMA-IR was calculated as follows: fasting insulin
(mU/ml)*fasting glucose (mg/dl)/405.
Results
Effect of IL-6 inhibition on inflammatory parameters in
human subjects
Tocilizumab is a monoclonal antibody against the IL-6 receptor
which is given at a dosage of 8 mg/kg body weight intravenously
for a 4 weeks period. In order to ensure reliable effects of this
antibody in the subjects examined, we first measured IL-6 serum
levels during Tocilizumab treatment. At baseline, IL-6 levels were
measured as 18.068.5 pg/ml with a minimum of 2.0 pg/ml and a
maximum of 98.0 pg/ml. As expected, blockade of the IL-6
receptor resulted in compensatory up-regulation of IL-6 serum
levels to 34.568.5 pg/ml after one month and 39.2613.2 pg/ml
after three months of therapy which has been shown in
Tocilizumab treated patients before [18]. We next compared C-
reactive protein levels and leukocyte cell count before and after
three months of treatment. As shown in figure 1, both
inflammatory parameters decreased significantly due to Tocilizu-
mab therapy. In respect to the clinical response 8/11 patients
reported a significant reduction in symptoms of their rheumatoid
disease. In these patients, Tocilizumab therapy was prolonged for
more than 6 months after the end of the present study. 3/11
patients reported no or only mild improvement of clinical
symptoms and Tocilizumab therapy was discontinued after the
three months of the study period.
Effect of IL-6 inhibition on body mass index and
adipokine serum levels in human subjects
Having shown a significant immunological response of the
subjects to Tocilizumab, we next aimed to examine metabolic
parameters. Mean body mass index was 28.061.8 kg/m
2 before
and 28.361.7 kg/m
2 after 3 months of treatment and therefore
was not significantly altered due to inhibition of IL-6 signalling.
Leptin levels at baseline were 38.3568.0 ng/ml and were not
significantly altered throughout the study period (fig. 2) which is in
agreement with previous reports showing that leptin levels are
closely related to body mass index [19]. Adiponectin levels were
unchanged within the first month of treatment, but exhibited a
significant up-regulation after 3 months of Tocilizumab therapy
(fig. 2). The ratio of leptin to adiponectin (LAR) therefore
accounted to 4.161.0 at baseline and was reduced to 3.560.7
after one month and 2.660.7 after three months of the study
period.
Effect of IL-6 inhibition on insulin sensitivity of human
subjects
We next aimed to investigate if insulin sensitivity is affected by
inhibition of IL-6 signalling in human subjects with rheumatoid
diseases. Therefore we first measured fasting plasma glucose and
fasting serum insulin levels and calculated the HOMA-IR (fig. 3).
When the study was started, mean HOMA-IR was 4.961.1 which
reflects a moderate degree of insulin resistance of the study
population, which is most likely due to inflammation and/or
glucocorticoid treatment. Of importance, the patients were
advised not to change the steroid dosage throughout the study
period to ensure the metabolic effects observed are solely due to
Tocilizumab. After the first month of treatment the HOMA-IR
did not significantly change compared to baseline (fig. 3).
However, at the end of the study period the HOMA-IR
significantly decreased, indicating enhanced insulin sensitivity
due to inhibition of IL-6 signalling. To substantiate this finding we
also calculated the LAR, a novel marker for insulin resistance [20].
In complete agreement with the HOMA-IR, the LAR was
unaltered within the first month of the study period but was
significantly reduced after 3 months of Tocilizumab therapy (fig. 2).
Mean glycosylated HbA1c levels of these non-diabetic patients
were within the normal range at baseline and did not change
significantly throughout the study period (table 2). Taken together,
the two independent parameters, HOMA-IR and LAR, both
suggest that inhibition of IL-6 signalling in human subjects with
rheumatoid diseases improves insulin sensitivity.
Figure 1. Effect of IL-6 inhibition on inflammatory parameters
in human subjects. Data are expressed as Means 6 SEM. *=p,0.05.
doi:10.1371/journal.pone.0014328.g001
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In previous reports it has been suggested that cholesterol levels
might be altered by Tocilizumab treatment [21]. In this respect we
also noticed a slight increase in LDL as well as HDL cholesterol
levels (table 2). Also, triglyceride levels were found to be slightly
elevated during treatment (table 2). However, these changes did
not reach statistical significance. In addition, we measured
Lipoprotein (Lp) (a) levels in the present study since this metabolite
is known to be an independent cardiovascular risk factor. Mean Lp
(a) levels were 34.5612.8 mg/dl when the study was started. Of
importance, already after one month of treatment, Lp (a) levels
decreased significantly. As shown in figure 4, this effect persisted
till the end of the study suggesting that IL-6 signalling is involved
in the regulation of Lp (a) metabolism in humans.
Discussion
Since 2001 several population based studies have shown a
positive correlation of IL-6 serum levels and insulin resistance in
human subjects [17,22–24]. However, the association of IL-6 and
type 2 diabetes is not well understood to date, as several studies in
rodents and humans have reported contradictory results. For
example, a common polymorphism in the IL-6 gene, -174G.C,
has been found to be associated with risk for type 2 diabetes in the
majority of population-based human studies [25]. However, in the
largest of these studies performed in Denmark in 2005, an
independent association of the IL6-174G allele with type 2 diabetes
was not found [26]. Furthermore, targeted ablation of the IL-6 gene
in one mouse model resulted in mature onset obesity and insulin
resistance [27] while a second, independent study on IL-6
2/2 mice,
did not exhibit differences in body weight compared to wild type
animals [28]. In addition to genetic modifications of rodents, studies
have been reported using neutralizing IL-6 antibodies in mice,
which is an experimental approach comparable to our study design.
Interestingly, in these experiments, inhibition of IL-6 signalling in
obese mice increased hepatic insulin sensitivity [29], suggesting that
IL-6 in an obese organism might cause insulin resistance.
IL-6 is a 26 kD protein that acts through a receptor complex
consisting of two subunits, gp130 and a ligand specific alpha chain,
IL-6Ra (for review of IL-6 action and metabolism see [30]).
Stimulation of this receptor complex activates the Janus kinase (Jak)-
STAT (signal transducer and activator of transcription) pathway
which is known to induce suppressor of cytokine signalling (SOCS)-3
expression [31]. SOCS3 has been demonstrated to induce a serine
phosphorylation of insulin receptor substrate (IRS)-1 which is known to
impair insulin signalling [32]. These findings suggest a molecular
mechanism by which IL-6 induces insulin resistance. Interestingly, it
also has been found that, both, IL-6 serum levels and insulin
resistance increase with age, indicating that IL-6 might also be
involved in the molecular regulation of aging [33].
Several studies have suggested, that IL-6 might be important in
the development of insulin resistance and type 2 diabetes, however,
a causal relationship in humans has not been proven so far.
Therefore, in the present study we have examined effects of
Tocilizumab therapy on metabolic parameters. Tocilizumab is a
humanmonoclonalantibodyselectivelyinhibitingIL-6 signallingby
blocking its receptor. Treatment with this antibody resulted in a
significant reduction of insulin resistance as shown by a decrease of
the HOMA-IR. We did not perform clamp experiments in the
Figure 2. Effect of IL-6 inhibition on body weight and adipokine serum levels in human subjects. Data are expressed as Means 6 SEM.
*=p,0.05.
doi:10.1371/journal.pone.0014328.g002
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adiponectin ratio (LAR). This parameter has recently been shown
to correlate very closely with the grade of insulin resistance
measured by euglycemic clamp studies and HOMA index in more
than 1000 human subjects [20]. In agreement with the decrease in
HOMA-IR, we observed a significant reduction of the LAR during
Tocilizumab treatment, indicating that insulin sensitivity is
enhanced due to inhibition of IL-6 signalling in humans with
rheumatoid disease. It also should be mentioned that in a recent
report low adiponectin levels were found to be strongly associated
with an increased risk for type 2 diabetes in humans [34]. The
significant increase in adiponectin levels in our study are thus in
keeping with favourable metabolic effects of Tocilizumab. One
might argue that these effects on insulin resistance may be an
indirect consequenceofa reductioninoverallinflammatoryactivity.
However, ina clinical studywith patients sufferingfromrheumatoid
arthritis, the monoclonal anti-TNF-a antibody adalimumab
reduced CRP levels without significant alteration of insulin
resistance [14], indicating that changes in overall inflammatory
activity per se do not necessarily alter insulin sensitivity. In
agreement to these findings, no significant correlation was found
between changes of CRP levels over time with changes of insulin
levels, HOMA-IR as well as LAR in the present study (table 3).
Several studies have shown increased LDL-cholesterol and
triglyceride levels in human subjects when treated with Tocilizu-
mab [21,35,36]. This finding was also observed in our cohort,
although the changes did not reach statistical significance. In
addition, we also measured Lp (a) levels in response to IL-6
inhibition. High Lp (a) levels haven been found to be associated
with an increased cardiovascular risk in human subjects in a meta-
analysis including several prospective studies with a total number
of 5436 human individuals and a mean follow up-period of 10
years [37]. Interestingly, in this meta-analysis the risk ratio did not
change following adjustment for other cardiovascular risk factors
suggesting that Lp (a) is an independent risk factor [37]. Lp (a)
contains an unique glycoprotein termed apolipoprotein (apo)-a
that is covalently linked to apoB100, the main apolipoprotein of
LDL cholesterol. Apo (a) bears a striking homology to the
sequence of plasminogen [38]. Lp (a) can inhibit fibrin clot lysis,
most likely due to inhibition of tissue plasminogen activator (tPA)-
mediated activation of plasminogen to its active form plasmin [39].
From a pathophysiological point of view, Lp (a) has been found in
atherosclerotic lesions [40] where it is thought to link atheroscle-
Figure 3. Effect of IL-6 inhibition on insulin sensitivity of
human subject. Data are expressed as Means 6 SEM. *=p,0.05.
doi:10.1371/journal.pone.0014328.g003
Table 2. Metabolic parameters of the study population.
0 month 1 month 3 month
TG (mg/dl) 141.9615.1 170.8626.2 169.6627.0
LDL (mg/dl) 122.5611.2 122.7610.7 133.1612.0
HDL (mg/dl) 53.666.5 61.065.0 63.065.1
Lp(a) (mg/dl) 34.5612.8 24.367.6
(a) 19.966.3
(b)
Glucose (mg/dl) 90.564.5 82.762.1 87.562.7
HbA1c (%) 5.461.5 5.360.1 5.260.1
TG= triglycerides, LDL= LDL-cholesterol, HDL= HDL-cholesterol, HbA1c=
glycosylated haemoglobin A1c levels.
(a)=p ,0.05 compared to 0 month,
(b)=p ,0.05 compared to 0 month. Means 6 SEM.
doi:10.1371/journal.pone.0014328.t002
IL-6 Effect on Metabolism
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World monkeys and absent in common laboratory animals [41].
In humans, the serum concentration of Lp (a) is known to be
mostly determined by genetic factors, however, secondary factors
such as acute phase response (APR) have been shown to increase Lp
(a) levels [42]. Moreover, it has been shown that IL-6 is an
important pro-inflammatory cytokine in APR and a correlation
between IL-6 and Lp (a) levels has been demonstrated [42]. The
data obtained in the present study indicate that serum IL-6 levels
are not only correlated to Lp (a) but that this cytokine is of causal
relevance in the regulation of Lp (a) metabolism in humans. Since
patients with inflammatory diseases are on increased cardiovas-
cular risk compared to human subjects without immunological
abnormalities [43], lowering of Lp (a) levels due to Tocilizumab
treatment might be beneficial in such patients.
In the present study we examined the effect of IL-6 inhibition on
insulin resistance in human subjects with a rheumatoid disease. Our
data suggest, collectively, that IL-6 might be of causal relevance in
impaired insulin sensitivity in humans. Furthermore, we show for
the first time that inhibition of IL-6 signalling lowers Lp (a) levels
which might positively affect the cardiovascular risk of human
subjects.Italsoshouldbementioned thatthepresentstudyhassome
limitations which impact on the interpretation of the results. First,
the number of subjects is very small and all the patients included in
the study suffered from an immunological disease. Therefore it can
not be excluded, that the improvement in insulin sensitivity is due to
the reduction of overall inflammatory activity. Second, all of the
patients were treated with Tocilizumab because of their inflamma-
tory symptoms and no placebo control group was included, giving
the study a clear observational character. Third, we did not perform
hyperinsulinemic-euglycemic clamp experiments which are still
considered to be the gold standard to assess insulin resistance.
Fourth, the different drugs that the subjects had taken in addition to
Tocilizumabprovideanimportantinterferenceinthestudy.Finally,
the age of the 5 lean and 6 overweight/obese subjects range from 21
to 68 years and it is well known that age, menopausal status and the
time of menstrual cycle affect IL-6 levels. However, the data
obtained are in line with the results of Ogata et al. reported very
recently [44], showing a significant improve in haemoglobin A1c
levels of type 2 diabetic subjects with rheumatoid arthritis when
treated with Tocilizumab also indicating favourable effects of
Tocilizumab on glucose metabolism in humans.
From a pathophysiological point of view, the results obtained by
Ogata et al. [44] and the data presented here give promising
evidence for future studies using Tocilizumab as a tool to examine
the effect of IL-6 on insulin sensitivity in human individuals not
suffering from an immunological disease to further clarify the role
of IL-6 in the pathogenesis of type 2 diabetes. Obviously, such
studies are needed before any more definite conclusions can be
drawn. However, from a clinical point of view, the data presented
here might have direct implications for rheumatologists, since
many patients with rheumatoid diseases additionally suffer from
Lp (a) abnormalities and therefore might benefit immunologically
and metabolically form a treatment with the IL-6 receptor
antibody Tocilizumab.
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